Emre Koca, Polly Ann Niravath, Joe Ensor, Tejal Amar Patel, Xiaoxian Li, Pej Hemati, Helen Wong, Wei Qian, Toniva Boone, Jing Zhao, Priya V Ramshesh, Adam Louis Cohen, Asha Murthy, Sindhu Nair, Jorge German Darcourt, Anna Belcheva, Virginia G Kaklamani, Jenny Chee Ning Chang
INTRODUCTION: Neoadjuvant endocrine therapy is often utilized to downstage Estrogen Receptor-positive (ER+) breast cancer prior to surgery. However, this approach is sometimes met with endocrine resistance mechanisms within the tumor. This trial examines the safety and efficacy of tamoxifen in combination with an mTORC1/2 inhibitor, TAK-228, in the neoadjuvant treatment of ER+ breast cancer. METHODS: In this single-arm, open-label trial, pre- and post-menopausal women were enrolled to receive neoadjuvant tamoxifen (20 mg daily) with TAK-228 (30 mg weekly) for 16 weeks prior to surgery...
July 2021: Breast Cancer Research and Treatment